Dissecting the role of aberrant DNA methylation in human leukaemia.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 25997600.
- Also identified by DOI 10.1038/ncomms8091 and PMC identifier 4443494.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder characterized by the genetic translocation t(9;22)(q34;q11.2) encoding for the BCR-ABL fusion oncogene. However, many molecular mechanisms of the disease progression still remain poorly understood. A growing body of evidence suggests that the epigenetic abnormalities are involved in tyrosine kinase resistance in CML, leading to leukaemic clone escape and disease propagation. Here we show that, by applying cellular reprogramming to primary CML cells, aberrant DNA methylation contributes to the disease evolution. Importantly, using a BCR-ABL inducible murine model, we demonstrate that a single oncogenic lesion triggers DNA methylation changes, which in turn act as a precipitating event in leukaemia progression.
Medical subject headings
- DNA Methylation
- Genes, abl
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive